Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-09
2006-05-09
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000, C435S007100
Reexamination Certificate
active
07041642
ABSTRACT:
Light emitting compounds of the formula:where R1is a light-emitting moiety, R2is a bombesin-like peptide and fragment, derivative or analog thereof and L is a linker moiety, which may be present or absent. The peptide is linked at a first amino acid position to (C—X) which, in turn, is selected from the group including C═O, C═S, CH(OH), C═C=O, C═NH, CH2, CH(OR), CH(NR), CH(R), CR3R4, and C(OR3)OR4where R, R3, and R4are alkyl moieties or substituted alkyl moieties. Optionally the compound may include a linker moiety between the peptide and the C—X binding group. Preferably, the compound exhibits substantial biological activity in the presence of receptors having affinities for bombesin-like peptides.
REFERENCES:
patent: 4046633 (1977-09-01), Keutel
patent: 5248782 (1993-09-01), Haugland
patent: 5274113 (1993-12-01), Kang et al.
patent: 5693679 (1997-12-01), Vincent et al.
patent: 5760188 (1998-06-01), Beaudet et al.
patent: 27 02 699 (1977-12-01), None
patent: 3912046 (1990-03-01), None
patent: 0 007 407 (1980-02-01), None
patent: 0 240 914 (1987-10-01), None
patent: 0 333 071 (1988-11-01), None
patent: 0 331 126 (1989-09-01), None
patent: 0 466 565 (1992-01-01), None
patent: 0 606 804 (1994-07-01), None
patent: 0 608 987 (1994-08-01), None
patent: 2 291 708 (1996-01-01), None
patent: 63051400 (1988-03-01), None
patent: WO 93/04194 (1993-03-01), None
patent: WO 93/18068 (1993-09-01), None
patent: WO 95/22341 (1995-08-01), None
patent: WO 96/31531 (1996-10-01), None
patent: WO 97/04311 (1997-02-01), None
Fluorescently-labeled gastrin releasing peptide was first introduced as a product by the assignee, Advanced Bioconcept, Ltd., under the trade name Fluo-GRP™ on Nov. 10, 1997.
Fluorescently-labeled neuromedin-C was first introduced as a product by the assignee, Advanced Bioconcept, Ltd., under the trade name Fluo-NMC™ on Feb. 10, 1998.
Amoscato et al., “Synthesis of Two Biologically Active Fluorescent Probes of Thymopentin”Peptide Protein Res., 29:177-186 (1987).
Ashworth et al., “Visualization of the Thyropoin-releasing Hormone Receptor And Its Ligand During Endocytosis And Recycling”Proc. Nat'l. Acad. Sci. USA, 92:512-516 (1995).
Beaudet et al., “Internalization And Intracellular Mobilization Of Neurotensin In Neuronal Cells”Biochemical Pharmacology, 47:43-52 (1994).
Beaudet et al., “Annales d'endocrinologie” p. L14, Sep. 1-3, 1994 (conference date).
Bowden et al., “Direct Observation of Substance P-induced Internalization of Neurokinin 1 (NK1) Receptors at Sites of Inflammation”Proc. Nat'l. Acad. Sci. USA, 91:8964-8968 (1994).
Bunnett et al., “Characterization Of Receptors Using Cyanine 3-labeled Neuropeptides”Peptides, 16:733-740, (1995).
Cardullo et al., “Speract Receptors Are Localized on Sea Urchin Sperm Flagella Using a Fluorescent Peptide Analog”Developmental Biology, 162:600-607 (1994).
Carraway et al., “The Isolation of a New Hypotensive Peptide, Neurotensin, From Bovine Hypothalami”J. of Biological Chemistry, 248:6854-6861 (1973).
Cauvin et al., “Properties and Distribution of Receptors For Pituitary Adenylate Cyclase Activating Peptide (PACAP) In Rat and Spinal Cord”Regulatory Peptides, 35:161-173 (1991).
Chard, Laboratory Techniques in Biochemistry and Molecular Biology, Elzevier Biomedical Press, New York.
Cheng et al., “Fluorescent Rhodamine-Labeled Thyroid Hormone Derivatives”FEBS Letters, 100:113-116 (1979).
Cheng et al., “Receptor-mediated Uptake Of 3,3′5-triiodo-L-thyronine By Cultured Fibroblasts”Proc. Nat'l. Acad. Sci. USA, 77:3425-3429 (1980).
Chersi et al., “Preparation And Utilization Of Fluorescent Synthetic Peptides”Biochemica et Biophysica Acta, 1034:333-336 (1990).
Christophe, “Type I Receptors For PACAP (A Neuropeptide Even More Important Than VIP?)”Biochimica et Biophysica Acta, 1154:183-199 (1993).
Cushman, “Spectrophotometric Assay And Properties Of the Angiotensin-converting Enzyme of Rabbit Lung”Biochemical Pharmacology, 20:1637-1648 (1971).
Epelbaum, “Somatostatin Receptors In the Central Nervous System”Basic and Chemical Aspects of Neuroscience, 4:17-28 (1992).
Faure et al., “Binding and Internalization of Neurotensin In Hybrid Cells Derived From Septal Cholinergic Neuronsα”Annals of the New York Academy of Sciences, 668:345-347 (1992).
Faure et al., “Synthesis of a Biologically Active Fluorescent Probe For Labeling Neurotensin Receptors”The Journal of Histochemistry and Cytochemistry, 42:755-763 (1994).
Garland et al., “Agonist-induced Internalization Of the Substance p (NK1) Receptor Expressed in Epithelia Cells”Biochem. J., 303:177-186 (1994).
Grady et al., “Delineation of the Endocytic Pathway of Substance P and Its Seven-Transmembrane Domains NK1 Receptor”Molecular Biology of the Cell, 6:509-524 (1995).
Grady et al., “Direct Observation Of Endocytosis Of Gastrin Releasing Peptide And Its Receptor”J. of Biol. Chem., 270:4603-04611 (1995).
Goldstein et al., “DAKLI: A Multipurpose Ligand With High Affinity And Selectivity For Dynorphin (kappa opioid) Binding Sites”Proc. Nat'l Acad. Sci., 85:7375-7379 (1988).
Guillon et al., “Lateral Mobility of the Phospholipase C-activating Vasopressin V1-type Receptor In A7r5 Smooth Muscle Cells: A Comparison With the Adenylate Cyclase-Coupled V2-receptor”Peptides, 13:7-11 (1992).
Haigler et al., “Visualization By Fluorescence of the Binding and Internalization of Epidermal Growth Factor In Human Carcinoma Cells A-431”Proc Natl Acad Sci USA, 75:3317-3321 (1978).
Haugland et al.,Noninvasive Techniques In Cell Biology, Wiley-Liss, Inc. (1990).
Haugland,Handbook of Fluorescent Probes and Research Chemicals—5thedition (1992).
Hazum et al., “Cluster Formation of Opiate (enkephalin) Receptors In Neuroblastoma Cells: Differences Between Agonists And Antagonists And Possible Relationships To Biological Functions”Proc. Nat'l. Acad. Sci., 77:3038-3041 (1980).
Hazum et al., “Fluorescent And Photo-affinity Enkephalin Derivatives: Preparation And Interaction With Opiate Receptors”Biochemical And Biophysical Research Communications, 88:841-846 (1979).
Jans et al., “Lateral Mobility of the Phospholipase C-activating Vasopressin V1-type Receptor In A7r5 Smooth Muscle Cells: A Comparison With the Adenylate Cyclase-coupled V2-Receptor”EMBO Journal, 9:2693-2699, (1990).
Kitabgi et al., (eds),Annals NY Acad. Sci., 668:Table of Contents.
Kohzuki et al., “Localization And Characterization of Endothelin Receptor Binding Sites In the Rat Brain Visualized ByIn VitroAutoradiography”Neuroscience, 42:245-260 (1991).
Maxfield, “Fluorescent Analogs Of Peptides And Hormones”Methods in Cell Biology, 29:13-28 (1989).
Melander et al.,125I-Galanin Binding Sites In the Rat Central Nervous SystemHandbook of Chemical Neuroanatomy, vol. II, Elsevier Publishers (1992).
Merchenthaler et al., “Anatomy And Physiology of Central Galanin-containing Pathways”Prog. Neurobiol., 40:711-769 (1993).
Nawa et al., “Nucleotide Sequences of Cloned cDNAs For Two Types of Bovine Brain Substance P Prescursor”Nature, 306:32-36 (1983).
Niedel et al., “Receptor-mediated Internalization of Fluorescent Chemotactic Peptide By Human Neutrophils”Science, 205:1412-1414 (1979).
Rivier, et al., “D-Trp8-somatostatin: An Analog Of Somatostatin More Potent Than the Native Molecule”Biochemical and Biophysical Research Communications, 65:746-751 (1975).
Roettger, et al., “Insulation Of A G Protein-coupled Receptor On the Plasmalemmal Surface Of the Pancreatic Acinar Cell”J. Cell Biol., 130: 579-590 (1995).
Rubanyi et al., “Endothelins: Molecular Biology, Biochemistry, Pharmacology, Physiology, And Pathophysiology”Pharmacological Reviews
Bonter Katherine J.
Desjardins Clarissa
Slon-Usakiewicz Jacek
Iandiorio & Teska
Lewis Amy
Low Christopher S. F.
PerkinElmer LAS, Inc.
LandOfFree
Fluorescent bombesin-like peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorescent bombesin-like peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorescent bombesin-like peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3586653